Texas Biomedical Research Institute focuses on basic and translational research to advance human health and eradicate infectious diseases. It has a history of developing significant therapies and vaccines.

Texas Biomedical Research Institute

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Adaptive Biotechnologies Corporation

Andelyn Biosciences is a full-service cell and gene therapy CDMO specializing in gene therapy and viral vector manufacturing.

Andelyn Biosciences

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.

Metric
Company Name	Texas Biomedical Research Institute	Adaptive Biotechnologies Corporation	Andelyn Biosciences	Arcturus Therapeutics Holdings Inc.
Symbol		ADPT		ARCT
MSH ID	ORG:TXBIOMED	COM:ADAPTIVEBIOTECH	COM:ANDELYNBIO	COM:ARCTURUSRX
Market	PRIVATE	STOCKS	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare	Healthcare & Health Services	Healthcare
Industry	Research and Development	Biotechnology	Biotechnology	Biotechnology
Country	US	US	US	US
Stage
Employee Count		709		180
Website	txbiomed.org	adaptivebiotech.com	andelynbio.com	arcturusrx.com
LinkedIn				arcturus-therapeutics
Founders

Metric
Market Cap	515.79M	585.23M
Enterprise Value
Monthly Web Traffic	7.23K
Web Traffic Growth	-0.12
Valuation
Raised Capital	125M

Metric
Revenue	170.28M	157.75M
Revenue (LTM)
Revenue (NTM)
Gross Profit	72.49M	154.79M
EBITDA	-179.38M	-1.20M
Operating Income	-201.61M	-4.15M
Net Income	-225.25M	-29.73M
EPS	-1.56	-1.12
Diluted EPS	-1.56	-1.12
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.54	1.02
Operating Profit Margin	-1.09	-0.42
EBITDA Margin	-1.05	-0.01
Net Profit Margin	-1.23	-0.17
Return on Equity	-0.62	-0.09
Return on Assets	-0.35	-0.06
Return on Capital Employed	-0.35	-0.20

ORG:TXBIOMED

Texas Biomedical Research Institute

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-2.72	9.33
P/B Ratio	1.38	3.31
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	4.82	10.51
EV Multiple	-1.23	-7.40

Metric
Days Sales Outstanding	63.40	47.66
Days Payables Outstanding	22.56	64.17
Days Inventory Outstanding	65.15	410.79
Operating Cycle	148.68	497.61
Cash Conversion Cycle	113.88	1.81K
Asset Turnover	0.29	0.40

Metric
Operating Cash Flow	-156.32M	-18.10M
Free Cash Flow	-167.02M	-21M
Cash Flow to Debt	-0.91	0.44
Operating Cash Flow/Sales	-0.77	0.11
Free Cash Flow Yield	-0.34	0.15

Metric
Cash & Equivalents	65.06M	347.00M
Accounts Receivable	2.03M	-29.30M
Inventory	14.45M
Goodwill	118.97M
Debt to Capitalization	0.37	0.11
Debt to Assets	0.14	0.11
Current Ratio	4.67	4.49
Quick Ratio	4.38	4.62

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.34	0.11
R&D to Revenue	0.69	0.62
SG&A to Revenue	0.48	0.18